Burning Rock Biotech : Q4 2021 Presentation Slides

Burning Rock Biotech Limited

4Q2021 results presentation

BNR US Equity 22 Mar 2022

Disclaimer

This presentation has been prepared by Burning Rock Biotech Limited (the "Company") solely for information purpose and has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of its affiliates, advisers, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its affiliates, advisers or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed.

Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company's intent, beliefs or current expectations about the future. These statements can be recognized by the use of words such as "expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident" or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances.

This presentation does not constitute an offer to sell or issue or an invitation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No part of this presentation shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

THE INFORMATION CONTAINED IN THIS DOCUMENT IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION. THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER. ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS PRESENTATION IN WHOLE OR IN PART IS UNAUTHORIZED.

By viewing, accessing or participating in this presentation, participants hereby acknowledge and agree to keep the contents of this presentation and these materials confidential. Participants agree not to remove these materials, or any materials provided in connection herewith, from the conference room where such documents are provided. Participants agree further not to photograph, copy or otherwise reproduce this presentation in any form or pass on this presentation to any other person for any purpose, during the presentation or while in the conference room. Participants must return this presentation and all other materials provided in connection herewith to the Company upon completion of the presentation. By viewing, accessing or participating in this presentation, participants agree to be bound by the foregoing limitations. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

2

Our value-building blocks

Extending leadership of NGS-based precision oncology from late-stage patients to earlier stages, driving the next phase of growth

New Businesses

Large market potential

At pipeline or early commercial stage

Common

Infrastructure

Accelerating growth of

new businesses

Base Business

Commercial stage

Early Detection	MRD	Biopharma
Asymptomatic population	Early-stage oncology	Global CDx partner for
	patients	pivotal trials of targeted
		drugs. Pharma R&D

• Strong brand to support new product launches & attract talent
• Broad industry network and synergy across different business units
• Large volumes supporting lower cost & faster innovation

Therapy Selection

Late-stage oncology patients

3

Recap of 2021 and recent progress

		• Achieved 38% volume growth year-on-year, reaching 70k+ units (central-lab and in-hospital
		combined) during 2021, out-growing industry
Therapy selection	• Strong market share gain through in-hospital strategy; in-hospital volume growth of 63% in 2021
		• 18% revenues growth to RMB508m, slightly above revised guidance of RMB500m1
		• Achieved NMPA approval of our second NGS kit2
		• Completed product development, based on a personalized approach
	MRD	• First datasets (NSCLC3 and CRC4 post-operative prognosis) reading out at AACR
		• Commercial launch in March 2022
	Biopharma	• Fast build-up of backlog projects. Contract value of RMB183m signed during 2021,
	5.7x vs. 2020
		• Clinical - 9-cancer test development on track. First large cohort (PROMISE study,
	Early detection	c. 2,000 participants) completed enrollment and reading out in 2022
Notes:
1	"Lower unit price in in-hospital channel vs. central-lab dragged blended ASP	4
2	Details in our announcement on 15th Mar 2022, Burning Rock Secures Second NGS Kit Approval from the NMPA
3	Non-small cell lung cancer
4	Colorectal cancer

2022 outlook

	• New product launches to expand into additional indications1
	• Continued drive towards in-hospital testing, with accelerating number of newly contracted
Therapy selection	hospitals, and volume ramp of existing hospitals
	• Accelerated revenue growth vs. 2021 (initial 2022 revenue guidance of RMB620m, +22%)
	• Efficiency improvement, with selling expenses as % of revenues to shrink vs. 2021
MRD	• Commercial ramp-up
• Additional studies with additional cancer types under planning
Biopharma	• Continued build-up of project backlog
• Higher contribution to overall revenues vs. 2021
	• Clinical - First intended-use population multi-cancer interventional study in China (PREVENT
Early detection	study) to launch in 2022
• Commercial - driving increased product contracting with hospital health check-up departments

Notes:
1 DetermaRx for early stage lung cancer, myChoice HRD Plus as a gold-standard for HRD score	5